Skip to main content
    H

    Haemonetics Corporation (HAE)

    Official site

    HEALTHCARE • MEDICAL DEVICES • NYSE

    $120.97
    -0.37 (-0.30%)

    Market Cap: $5.53B

    Last updated: Nov 17, 2026 at 4:28 PM ET

    Haemonetics Corporation (HAE) Statistics

    Updated Nov 17, 2026. Figures from company filings and market prices; estimates from consensus analysts.

    Haemonetics (HAE) has a market cap of $5.53B and an enterprise value of $6.39B. Its share count is down 4.39% from a year earlier.

    Total Valuation

    Enterprise value is 15.62% above the market cap, as debt exceeds cash.

    Market Cap$5.53B
    Enterprise Value$6.39B
    Latest price (Nov 17, 2026)$120.97

    Key Dates

    The next earnings report is expected on Feb 3, 2027, covering the quarter ending Dec 31, 2026.

    Next Earnings DateFeb 3, 2027 (expected)
    Last Earnings DateNov 5, 2026
    Fiscal Year EndMarch

    Share Statistics

    The share count rose 0.31% in the quarter ended Sep 30, 2026 and shrank 5.45% a year over 2 years.

    Shares Outstanding45.50M
    Shares Change (YoY)-4.39%
    Shares Change (QoQ)+0.31%
    Share Count Growth (2Y CAGR)-5.45%

    Valuation Ratios

    Sales and book value multiples are 4.0x and 6.1x. Its year-end P/E ranged from 16.3x to 46.0x from 2016 to 2025.

    P/E Ratio23.8x
    Forward P/E22.5x
    P/S Ratio4.0x
    Forward P/S3.8x
    P/B Ratio6.1x
    P/FCF Ratio18.5x
    P/OCF Ratio16.0x
    PEG Ratio2.6

    Valuation history and multiples

    Enterprise Valuation

    Counting debt and cash, the company is valued at 25.2x EBITDA and 21.3x free cash flow.

    EV / Earnings61.5x
    EV / Sales4.6x
    EV / EBITDA25.2x
    EV / EBIT45.0x
    EV / FCF21.3x

    Price Statistics

    The stock is up 64.61% over 52 weeks and trades 6.08% above its 50-day average.

    Beta (1Y)0.27
    52-Week Change+64.61%
    1-Month Change+1.89%
    3-Month Change+11.59%
    6-Month Change+112.79%
    5-Year Change+74.14%
    10-Year Change+258.13%
    Total Return (1Y)+64.61%
    Total Return (3Y CAGR)+13.28%
    Total Return (5Y CAGR)+16.69%
    Return vs SPY (1Y)+51.03%
    Max Drawdown (1Y)-40.06%
    Max Drawdown (3Y)-51.04%
    Sharpe Ratio (1Y)1.22
    Correlation with SPY (1Y)0.09
    50-Day Average$114.04
    200-Day Average$81.81
    52-Week Range$51.00 to $132.00
    RSI (14 Days)54.5
    Average Volume (20 Days)695.36K

    The 5 and 10 year changes compare month-end closes, adjusted for splits, through Oct 2026.

    Price chart

    Financial Position

    Current assets cover 2.84x current liabilities, and total debt is 1.25x shareholder equity.

    Current Ratio2.84x
    Quick Ratio1.83x
    Debt / Equity1.25x
    Debt / EBITDA4.44x
    Debt / FCF3.77x

    Returns and Efficiency

    Return on invested capital is 5.14% over the last 12 months, against a 5-year average of 5.96%.

    Return on Equity (ROE)11.56%
    Return on Assets (ROA)4.31%
    Return on Invested Capital (ROIC)5.14%
    Return on Capital Employed (ROCE)6.73%
    ROE (5Y Average)12.96%
    ROA (5Y Average)4.91%
    ROIC (5Y Average)5.96%
    Asset Turnover0.57x
    Inventory Turnover1.82x
    Receivables Turnover6.27x
    Cash Conversion Cycle216 days

    Taxes

    Income tax took 26.83% of pretax income over the last 12 months.

    Income Tax (TTM)$38.10M
    Effective Tax Rate26.83%

    Scores

    HAE has an Altman Z-Score of 3.44, in the safe zone above 2.99, and a Piotroski F-Score of 7 of 9, in the average band of 3 to 7.

    Altman Z-Score3.44
    Altman Z ZoneSafe
    Piotroski F-Score7 of 9
    Piotroski StrengthAverage

    Income Statement

    Revenue of $1.38B over the last 12 months is up 4.11% from the 12 months before.

    Revenue$1.38B
    Revenue Growth (YoY)+4.11%
    Gross Profit$824.31M
    Operating Income$176.95M
    Pretax Income$142.01M
    Net Income$103.91M
    EBITDA$252.91M
    EBIT$142.01M
    Reported EPS (TTM)$5.09

    Trailing 12 months through Sep 30, 2026.

    Full financial statements

    Balance Sheet

    Shareholder equity funds 37.28% of the $2.41B in total assets.

    Cash and Equivalents$260.71M
    Total Debt$1.12B
    Net Debt$863.05M
    Net Debt Per Share$18.97
    Working Capital$554.69M
    Shareholder Equity$898.50M
    Book Value Per Share$19.75
    Tangible Book Value-$184.97M
    Total Assets$2.41B
    Total Liabilities$1.51B

    Balance sheet as of Sep 30, 2026.

    Full balance sheet

    Cash Flow

    After $46.69M of capital spending, operating cash flow left $298.24M of free cash flow.

    Operating Cash Flow$344.93M
    Capital Expenditures$46.69M
    Free Cash Flow$298.24M
    FCF Per Share$6.56
    Depreciation and Amortization$110.90M

    Trailing 12 months through Sep 30, 2026.

    Full cash flow statement

    Margins

    The operating margin is 12.80%, against a 5-year average of 12.43%.

    Gross Margin59.63%
    Operating Margin12.80%
    Pretax Margin10.27%
    Net Margin7.52%
    EBITDA Margin18.29%
    EBIT Margin10.27%
    FCF Margin21.57%
    Gross Margin (5Y Average)54.09%
    Operating Margin (5Y Average)12.43%
    Net Margin (5Y Average)8.57%

    Growth

    Revenue grew 4.51% a year over 3 years, and EPS 17.93% a year.

    Revenue Growth (3Y CAGR)+4.51%
    Revenue Growth (5Y CAGR)+8.91%
    EPS Growth (3Y CAGR)+17.93%
    EPS Growth (5Y CAGR)+16.16%
    FCF Growth (3Y CAGR)+47.15%
    FCF Growth (5Y CAGR)+29.41%
    Operating Income Growth (3Y CAGR)+0.15%
    Book Value Per Share Growth (2Y CAGR)-3.95%

    Revenue and profit by year

    Dividends and Yields

    HAE does not pay a dividend. Its free cash flow yield is 5.42%.

    Earnings Yield4.20%
    FCF Yield5.42%
    Buyback Yield1.82%
    Shareholder Yield1.82%

    Stock Splits

    The last split was a 2-for-1 forward split on Dec 3, 2012.

    Last Split DateDec 3, 2012
    Split TypeForward split
    Split Ratio2:1

    Peer Position

    Against 9 similar companies, HAE has the 6th highest P/E.

    P/E Ratio23.8x vs 31.5x median
    P/S Ratio4.0x vs 3.5x median
    ROIC5.14% vs 6.99% median
    Revenue Growth (Trailing 4 Quarters, YoY)+4.11% vs +12.52% median

    Competitors compared

    Analyst Forecast

    Consensus estimates put revenue growth at 9.07% and EPS growth at 11.70% a year over the next 2 fiscal years.

    Revenue Growth Forecast (2Y CAGR)+9.07%
    EPS Growth Forecast (2Y CAGR)+11.70%

    Analyst estimates by year

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    GNG Valuation

    GNG viewFairly valued

    GNG fair value is part of GNG Pro. See plans

    Frequently Asked Questions About HAE

    What is HAE's market cap?

    Haemonetics has a market cap of $5.53B. Its enterprise value, which adds debt and subtracts cash, is $6.39B.

    What is HAE's P/E ratio?

    Haemonetics has a trailing P/E ratio of 23.8x and a forward P/E of 22.5x.

    How many shares of HAE are outstanding?

    Haemonetics has 45.50M shares outstanding. The count is down 4.39% from a year earlier.

    Does HAE pay a dividend?

    No. Haemonetics does not pay a dividend.

    How much debt does HAE have?

    Haemonetics has $1.12B of total debt and $260.71M of cash and equivalents, a net debt position of $863.05M.